216 related articles for article (PubMed ID: 18164751)
21. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers.
Chan JK; Teoh D; Hu JM; Shin JY; Osann K; Kapp DS
Gynecol Oncol; 2008 Jun; 109(3):370-6. PubMed ID: 18395777
[TBL] [Abstract][Full Text] [Related]
22. Histological classification of ovarian cancer.
Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
[TBL] [Abstract][Full Text] [Related]
23. My approach to and thoughts on the typing of ovarian carcinomas.
McCluggage WG
J Clin Pathol; 2008 Feb; 61(2):152-63. PubMed ID: 17704261
[TBL] [Abstract][Full Text] [Related]
24. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.
Ye B; Skates S; Mok SC; Horick NK; Rosenberg HF; Vitonis A; Edwards D; Sluss P; Han WK; Berkowitz RS; Cramer DW
Clin Cancer Res; 2006 Jan; 12(2):432-41. PubMed ID: 16428483
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
Tanabe H; Nishii H; Sakata A; Suzuki K; Mori Y; Shinozaki H; Watanabe A; Ochiai K; Yasuda M; Tanaka T
Gynecol Oncol; 2004 Sep; 94(3):735-9. PubMed ID: 15350366
[TBL] [Abstract][Full Text] [Related]
26. eEF1A2 as a putative oncogene.
Lee MH; Surh YJ
Ann N Y Acad Sci; 2009 Aug; 1171():87-93. PubMed ID: 19723040
[TBL] [Abstract][Full Text] [Related]
27. LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma.
Lin CK; Chao TK; Lai HC; Lee HS
Am J Clin Pathol; 2012 Jun; 137(6):971-7. PubMed ID: 22586057
[TBL] [Abstract][Full Text] [Related]
28. Characterization of a putative ovarian oncogene, elongation factor 1alpha, isolated by panning a synthetic phage display single-chain variable fragment library with cultured human ovarian cancer cells.
Sharma S; Tammela J; Wang X; Arnouk H; Driscoll D; Mhawech-Fauceglia P; Lele S; Kazim AL; Odunsi K
Clin Cancer Res; 2007 Oct; 13(19):5889-96. PubMed ID: 17908984
[TBL] [Abstract][Full Text] [Related]
29. Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma.
Innamaa A; Jackson L; Asher V; Van Shalkwyk G; Warren A; Hay D; Bali A; Sowter H; Khan R
Anticancer Res; 2013 Apr; 33(4):1401-8. PubMed ID: 23564779
[TBL] [Abstract][Full Text] [Related]
30. [Morphometrical and immunohistochemical criteria of prognosis in patients with serous and mucinous ovarian carcinoma].
Kolosov AE; Novichkov EV
Arkh Patol; 2003; 65(5):29-32. PubMed ID: 14664145
[TBL] [Abstract][Full Text] [Related]
31. DNA fragmentation factor (DFF45): expression and prognostic value in serous ovarian cancer.
Brustmann H
Pathol Res Pract; 2006; 202(10):713-20. PubMed ID: 16962250
[TBL] [Abstract][Full Text] [Related]
32. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
Takao M; Okamoto A; Nikaido T; Urashima M; Takakura S; Saito M; Saito M; Okamoto S; Takikawa O; Sasaki H; Yasuda M; Ochiai K; Tanaka T
Oncol Rep; 2007 Jun; 17(6):1333-9. PubMed ID: 17487387
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions.
Slipicevic A; Øy GF; Askildt IC; Holth A; Hellesylt E; Flørenes VA; Davidson B
Hum Pathol; 2009 Apr; 40(4):527-37. PubMed ID: 19121847
[TBL] [Abstract][Full Text] [Related]
34. The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.
Tsuchiya T; Nakahama K; Asakawa Y; Maemura T; Tanaka M; Takeda S; Morita M; Morita I
Gynecol Endocrinol; 2009 Feb; 25(2):104-9. PubMed ID: 19253105
[TBL] [Abstract][Full Text] [Related]
35. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications.
Köbel M; Kalloger SE; Santos JL; Huntsman DG; Gilks CB; Swenerton KD
Gynecol Oncol; 2010 Jan; 116(1):50-6. PubMed ID: 19822358
[TBL] [Abstract][Full Text] [Related]
36. An interleukin-6 gene promoter polymorphism influences the biological phenotype of ovarian cancer.
Hefler LA; Grimm C; Ackermann S; Malur S; Radjabi-Rahat AR; Leodolter S; Beckmann MW; Zeillinger R; Koelbl H; Tempfer CB
Cancer Res; 2003 Jun; 63(12):3066-8. PubMed ID: 12810629
[TBL] [Abstract][Full Text] [Related]
37. Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.
Bellone S; Anfossi S; O'Brien TJ; Cannon MJ; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Cancer; 2009 Feb; 115(4):800-11. PubMed ID: 19117353
[TBL] [Abstract][Full Text] [Related]
38. Immunohistochemical localisation of carcinoembryonic antigen (CEA) in malignant epithelial ovarian tumours using monoclonal antibodies.
Gogate N; Deshmukh S
Indian J Pathol Microbiol; 1995 Apr; 38(2):199-201. PubMed ID: 8919110
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types.
Wang H; Rosen DG; Wang H; Fuller GN; Zhang W; Liu J
Mod Pathol; 2006 Sep; 19(9):1149-56. PubMed ID: 16729015
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary.
Palmer JE; Sant Cassia LJ; Irwin CJ; Morris AG; Rollason TP
Int J Gynecol Pathol; 2007 Oct; 26(4):395-403. PubMed ID: 17885489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
